In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin

Am J Cardiol. 2002 Jan 1;89(1):61-4. doi: 10.1016/s0002-9149(01)02165-8.
No abstract available

MeSH terms

  • Angioplasty, Balloon, Coronary / economics*
  • Coronary Artery Disease / therapy*
  • Cross-Over Studies
  • Double-Blind Method
  • Eptifibatide
  • Female
  • Hospital Costs*
  • Humans
  • Length of Stay
  • Male
  • Middle Aged
  • Peptides / economics
  • Peptides / therapeutic use*
  • Platelet Aggregation Inhibitors / economics
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
  • Randomized Controlled Trials as Topic
  • Stents
  • United States

Substances

  • Peptides
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Eptifibatide